July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Comparison of Therapeutic Effect and Hyperreflective Foci on Optical Coherence Tomography between Bevacizumab and Dexamethasone Implant for Macular Edema in Branch Retinal Vein Occlusion according to the Symptom Duration
Author Affiliations & Notes
  • Dong Ho Park
    Ophthalmology, Kyungpook National University Hospital, Daegu, Korea (the Republic of)
  • Jae Rock Do
    Ophthalmology, Kyungpook National University Hospital, Daegu, Korea (the Republic of)
  • Ji Yeon Do
    Ophthalmology, Kyungpook National University Hospital, Daegu, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Dong Ho Park, None; Jae Rock Do, None; Ji Yeon Do, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1145. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dong Ho Park, Jae Rock Do, Ji Yeon Do; Comparison of Therapeutic Effect and Hyperreflective Foci on Optical Coherence Tomography between Bevacizumab and Dexamethasone Implant for Macular Edema in Branch Retinal Vein Occlusion according to the Symptom Duration. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1145.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the effect of intravitreal bevacizumab and dexamethasone implant for macular edema (ME) in branch retinal vein occlusion (BRVO) according to symptom duration and investigate the correlation between duration of ME and hyperreflective foci (HRF) on spectral-domain optical coherence tomography (SD-OCT).

Methods : A retrospective review was conducted involving total 139 eyes (139 patients) with ME due to BRVO which had either only intravitreal bevacizumab injection (IVB) or dexamethasone implant injection (IVD) pro re nata (PRN) for at least 6 months. According to the ME duration, each group was divided into two subgroups (<3 months vs ≥3 months). Baseline HRF in spectral-domain OCT according to the ME duration was compared at inner and outer retinal layers. At 6 months after the initial injection, changes in number of HRF, central subfield macular thickness (CSMT) and best-corrected visual acuity (BCVA) were compared between IVB and IVD groups according to ME duration.

Results : Among the total 139 eyes, 70 eyes (50.4%) had ME duration <3 months and 69 eyes (49.6%) had ME duration ≥3 months. In eyes with ME <3months and ME duration ≥3 months, the mean baseline inner HRF was 9.3 ± 6.3 and 9.1 ± 4.4. Eyes with ME ≥3 months had significantly more baseline outer retinal HRF than eyes with ME <3months (P<0.001). In the IVB group, number of HRF in the inner layer decreased at 6 months compared to the baseline in both eyes with ME <3months and ME ≥3 months (P<0.001). However, number of HRF in the outer layer increased at 6 months compared to the baseline in both eyes with ME <3months and ME ≥3 months (P<0.05). In the IVD group, number of HRF in the inner layer decreased at 6 months compared to the baseline in both eyes with ME < 3months and ME ≥3 months (P<0.001). In addition, number of HRF in the outer layer decreased at 6 months compared to the baseline in eyes with ME ≥3 months (P<0.001). In eyes with ME duration ≥3months, the IVD group showed improved BCVA and CSMT changes than the IVB group showed (P<0.01).

Conclusions : The IVD group showed more HRF reduction with better functional and anatomical improvement than the IVB group in eyes with ME ≥3 months. This could implicate that inflammatory components are more involved in eyes with longer duration of ME due to BRVO.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×